Oxford Nanopore at AMP 2026
:quality(80))
Overview
The Association for Molecular Pathology (AMP) Annual Meeting & Expo features more than 200 exhibiting companies, 60 educational sessions, nearly 400 poster presentations, and 3,000+ attendees/exhibitors.
Oxford Nanopore will be located at Booth 604, and will host 2 Corporate Workshops on Wednesday, November 11, and a lightning talk on Thursday, November 12.
Exhibits will be open from November 12 to November 14.
Oncology Workshop
Rapid tumor profiling with real-time nanopore sequencing
Molecular diagnosis and methylation-based classification are increasingly important for the comprehensive characterization of cancer. In this sponsored session, speakers will demonstrate how Oxford Nanopore native DNA sequencing and Adaptive Sampling can enable rapid profiling of CNS tumors and leukemia. Adaptive Sampling provides software-defined, on-sequencer target enrichment with low-pass whole genome, without the need for baits or a lengthy enrichment workflow. Combined with real-time sequencing and direct detection of DNA methylation, this approach accelerates access to rich genomic and epigenomic insights. Speakers will highlight how rapid methylation-based classification alongside genomic analysis is advancing molecular testing workflows and explore its potential for clinical implementation.
Date: Wednesday, November 11, 2026
Time: 12:00 pm-12:50 pm PST
Location: Tahoma 1, Level 3, Arch at 800 Pike
Agenda
12:00–12:50 PM PST | Talk title | Speaker |
|---|---|---|
12:00–12:05 PM | Welcome and introductions | Ellie Juarez, Oxford Nanopore Technologies |
12:05–12:25 PM | Methylation Classifiers in Action (CNS, Solid Tumors, and Leukemia) | Lennart Kester, Princess Maxima Center for Pediatric Oncology |
12:25–12:50 PM | Advancing precision oncology through rapid multi-omics diagnostics | Professor Marilyn Li, Children's Hospital of Philadelphia |
Rare Disease Workshop
Enabling more complete rare disease analysis with long-read sequencing
Rare disease research requires the detection of complex genomic variation that can be challenging to capture using traditional short-read sequencing approaches alone. This workshop will provide an overview of how long-read sequencing technologies are expanding genomic analysis through more comprehensive characterization of structural variants, repeat expansions, and other difficult-to-resolve genomic features. Through case studies and practical examples, attendees will explore how long-read sequencing can uncover biologically relevant variation missed by conventional methods, improving the resolution of challenging genomic regions, and broadening the scope of rare disease studies.
Date: Wednesday, November 11, 2026
Time: 01:00 pm-01:50 pm PST
Location: Tahoma 4, Level 3, Arch at 800 Pike
Agenda
1:00–1:50 PM PST | Talk title | Speaker |
|---|---|---|
1:00–1:05 PM | Welcome and introductions | Jesse Fox, Oxford Nanopore Technologies |
1:05–1:25 PM | Beyond conventional panels - Comprehensive analysis, genome and epigenome-wide | Cora Vacher, PhD, Oxford Nanopore Technologies |
1:25–1:50 PM | Long read sequencing: a new lens in understanding and diagnosing rare disease | Dr. Akash Kumar, Co-founder, MyOme |
Lightning Talk
Scalable analysis of short tandem repeat expansions using nanopore whole-genome sequencing and digital panels.
Date: Thursday, November 12, 2026
Time: 02:30 pm-02:45 pm PST
Location: Room 611–614
Speakers
Ellie Juarez
:quality(80))
- Job title
- Director, Segment Marketing Oncology
- Institution
- Oxford Nanopore Technologies
- Biography
Eleonora (Ellie) Juarez is currently the Director of the Oncology Market Segment at Oxford Nanopore Technologies. With her extensive cancer genomics experience and a doctorate in molecular and medical genetics, she drives the development of new oncology assays, enabling cancer researchers to answer the most complex biological questions using Oxford Nanopore sequencing.
Lennart Kester
:quality(80))
- Job title
- Princial Investigator
- Institution
- Princess Maxima Center for Pediatric Oncology
- Biography
Lennart Kester is a principal investigator at the Princess Máxima Center for Pediatric Oncology in Utrecht, the Netherlands, where his work focuses on translating novel molecular technologies into clinical diagnostics for childhood cancer. His research centers on rapid DNA methylation-based tumor classification using Oxford Nanopore Technologies sequencing, spanning central nervous system tumors, solid tumors, and leukemia. He has contributed to the development and clinical implementation of nanopore-based classifiers including STURGEON, TUCAN, and LAMPREY. A major focus of his work is moving these approaches beyond proof-of-concept studies and into routine diagnostic workflows, enabling rapid and accessible molecular classification for pediatric cancer patients.
Dr. Marilyn Li
:quality(80))
- Job title
- Professor of Pathology and Laboratory Medicine and Pediatrics
- Institution
- Children's Hospital of Philadelphia
- Biography
Marilyn M. Li, MD is Professor of Pathology and Laboratory Medicine and Pediatrics at the University of Pennsylvania Medical School, Children’s Hospital of Philadelphia, where she serves as Associate Chair for Healthcare Equity and Inclusion, Vice Chief of Genomic Diagnostics, and Director of Cancer Genomic Diagnostics. As an internationally recognized leader in cancer multiomics, precision oncology, and variant interpretation, Dr. Li's research integrates advanced multiomics and bioinformatics to improve cancer diagnosis, prognosis, treatment, and prevention. Dr. Li has authored over 150 peer-reviewed publications, led many national guideline initiatives, and founded the Cancer Genomics Consortium to advance high-quality genomic testing worldwide.
Jesse Fox
:quality(80))
- Job title
- Director, Regional Marketing, AMR
- Institution
- Oxford Nanopore Technologies
Cora Vacher
:quality(80))
- Job title
- Director, Segment Marketing
- Institution
- Oxford Nanopore Technologies
- Biography
Cora Vacher is the Market Segment Director for Human Genetic at Oxford Nanopore Technologies. Cora is passionate about genomics, in particular how genomics can help decipher and alleviate the burden of neurological diseases from neurodevelopmental to late onset neurodegenerative disorders. She came to the UK for a postdoctoral position on the genetics of Huntington’s disease in Cambridge and subsequently moved to commercial organisations.
Akash Kumar, MD, PhD
:quality(80))
- Job title
- Attending Physician at Stanford
- Institution
- Co-founder of MyOme
- Biography
Akash Kumar, M.D., Ph.D., is a clinical geneticist, an attending physician at Stanford University, and the co-founder of MyOme, where he oversees medical and scientific initiatives.
Philipp Rescheneder
:quality(80))
- Job title
- Senior Director, Bioinformatics Applications
- Institution
- Oxford Nanopore Technologies
- Biography
Philipp Rescheneder serves as Senior Director, Applications Bioinformatics at Oxford Nanopore Technologies. He leads a team focused on developing and supporting bioinformatics applications for Oxford Nanopore sequencing, working at the intersection of genomics, computational biology, and product development. Philipp collaborates with scientists, software developers, and external partners to translate complex biological questions into practical analysis tools and workflow prototypes that advance genomic research and real-world applications of nanopore sequencing.
